2023
Pre-operative chemoradiotherapy with or without induction chemotherapy for operable locally-advanced esophageal cancer
Peters G, Talcott W, Peters N, Dhanasopan A, Lacy J, Cecchini M, Kortmansky J, Stein S, Lattanzi S, Park H, Boffa D, Johung K, Jethwa K. Pre-operative chemoradiotherapy with or without induction chemotherapy for operable locally-advanced esophageal cancer. Journal Of Gastrointestinal Oncology 2023, 14: 1181-1192. PMID: 37435226, PMCID: PMC10331751, DOI: 10.21037/jgo-22-1005.Peer-Reviewed Original ResearchProgression-free survivalMedian progression-free survivalOverall survivalIC-CRTInduction chemotherapySingle-institution retrospective cohort studyPre-operative chemoradiotherapyAdvanced esophageal cancerAdvanced esophageal carcinomaPathologic complete responseRetrospective cohort studyKaplan-Meier methodSubset of patientsProportional hazards regressionCycles of inductionAdenocarcinoma histologyCRT cohortCohort studyComplete responsePathologic responseTreatment cohortsDistant metastasisHazards regressionEsophageal cancerEsophageal carcinoma
2016
Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study
Kasi PM, Kotani D, Cecchini M, Shitara K, Ohtsu A, Ramanathan RK, Hochster HS, Grothey A, Yoshino T. Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study. BMC Cancer 2016, 16: 467. PMID: 27412464, PMCID: PMC4944251, DOI: 10.1186/s12885-016-2491-y.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAntineoplastic AgentsChemotherapy-Induced Febrile NeutropeniaClinical Trials, Phase III as TopicCohort StudiesColorectal NeoplasmsDisease-Free SurvivalDose-Response Relationship, DrugDrug CombinationsDrug Resistance, NeoplasmFemaleHumansJapanKaplan-Meier EstimateMaleMiddle AgedPrognosisPyrrolidinesThymineTrifluridineUnited StatesUracilConceptsMetastatic colorectal cancerProgression-free survivalOverall survivalCohort studyGrade 2Median progression-free survivalRefractory metastatic colorectal cancerLonger progression-free survivalNeutrophil count decreaseCommon Terminology CriteriaBetter overall survivalKaplan-Meier methodChemotherapy-induced neutropeniaLog-rank testTerminology CriteriaAdverse eventsClinical characteristicsPatient demographicsStandard therapyTAS-102Colorectal cancerOutcome dataPatientsCount decreaseRegulatory approval